Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2006-05-09
2006-05-09
Smith, Lynette R. F. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S234100, C424S203100, C424S252100, C424S145100, C424S158100, C530S300000, C530S350000, C514S002600
Reexamination Certificate
active
07041296
ABSTRACT:
The present invention provides a method of treating or preventing inflammation in a subject, comprising administering to the subject an effective amount of cholera toxin subunit B. The present invention also provides a method of decreasing the activity of interferon gamma in a subject, comprising administering to the subject an effective amount of cholera toxin subunit B. Further provided is a method of decreasing the activity of IL-12 in a subject, comprising administering to the subject an effective amount of cholera toxin subunit B. Additionally, the present invention provides a method of treating or preventing a Th1 T-cell mediated autoimmune disorder in a subject, comprising administering to the subject an effective amount of cholera toxin subunit B.
REFERENCES:
patent: 4411888 (1983-10-01), Klipstein et al.
patent: 5214029 (1993-05-01), Viallet et al.
patent: 5681571 (1997-10-01), Holmgren et al.
patent: 5762931 (1998-06-01), Talwar et al.
patent: 5882653 (1999-03-01), Kaper et al.
patent: 5980898 (1999-11-01), Glenn et al.
patent: 6019973 (2000-02-01), Holmgren et al.
patent: 6030624 (2000-02-01), Russell et al.
patent: 6153203 (2000-11-01), Holmgren et al.
patent: 6255097 (2001-07-01), Meyer et al.
patent: 6287563 (2001-09-01), Williams et al.
patent: 6290962 (2001-09-01), Michetti et al.
patent: 6322796 (2001-11-01), Holmgren et al.
patent: 6365163 (2002-04-01), Holmgren et al.
patent: 6376460 (2002-04-01), Llewellyn-Smith
patent: 6440413 (2002-08-01), Hooreman
patent: 6576244 (2003-06-01), Weltzin et al.
patent: 6599509 (2003-07-01), Fox et al.
patent: 6607732 (2003-08-01), Morein et al.
patent: 6749856 (2004-06-01), Berzofsky et al.
patent: 2002/0044938 (2002-04-01), Fox et al.
patent: 2003/0049797 (2003-03-01), Yuki et al.
patent: WO 97/02045 (1997-01-01), None
patent: 97/05267 (1997-02-01), None
patent: WO 98/16248 (1998-04-01), None
patent: 99/18225 (1999-04-01), None
patent: WO 99/54452 (1999-10-01), None
Dr. Varga Laszlo et al, Allergy to Helicobacter pylori, Kazuisztika, pp. 359-361, Issue 6, 1992, English translation.
Whary, MT et al, Infection and Immunity, vol. 66(7), apges 3142-3148, Jul. 1998, Chronic Active Hepatitis induced by Helicobacter hepaticus in the A/JCr Mouse is associated with a Th1 cell mediated immune response.
Boirivant, M et al, The Journal of Immunology, 2001, vol. 166, pp. 3522-3532.
Johnansson, E et al, Infection and Immunity, Feb. 1998, pp. 514-520, vol. 66(2).
Kim, P et al, The Journal of Immunology, 1998, vol. 160, p. 1198-1203.
Rudin, A et al, Infection and Immunity, Jul. 1998, pp. 3390-3396, vol. 66(7).
Sobel, DO et al, Diabetes, vol. 47, pp. 186-191, 1998.
Boirivant, M et al, The Journal of Immunology, 2001, Vol. 166, pp. 3522-3532.
Johnansson, E et al, Infection and Immunity, Feb. 1998, pp. 514-520, Vol. 66(2).
Kim, P et al, The Journal of Immunology, 2001, Vol. 166, pp. 1198-1203.
Rudin, A et al, Infection and Immunity, Jul. 1998, pp. 3390-3396, Vol. 66(7).
Sobel, Do et al, Diabetes, Vol. 47, pp. 186-191, 1998.
Bergerot et al., “A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes”Proc. Natl. Acad. Sci. USA94:4610-4614 (Apr. 1997).
Boirivant et al., “Oral Administration of Recombinant Cholera Toxin Subunit B Inhibits IL-12 Mediated Murine Experimental Colitis”Gastroenterology118 (4 pt. 1 Supp. 2):2982.
Boirivant et al., “Oral Administration of Recombinant Cholera Toxin Subunit B Inhibits IL-12-Mediated Murine Experimental (Trinitrobenzene Sulfonic Acid) Colitis”J. Immunol. 166(5):3522-3532 (Mar. 1, 2001).
Boirivant et al., “Oxazolone Colitis: A Murine Model of T Helper Cell Type 2 Colitis Treatable with Antibodies to Interleukin 4”J. Exp. Med. 188(10):1929-1939 (Nov. 16, 1998).
Braun et al., “Cholera Toxin Suppresses Interleukin (IL)-12 Production and IL-12 Receptor β1 and β2 Chain Expression”J. Exp. Med. 189(3):541-552 (Feb. 1, 1999).
Burkart et al., “Suppression of Autoimmune Diabetes by Cholera Toxin B Chain: Role of Innate Immunity”Diabetologia42(Suppl. 1):A103.
de Haan et al., “Mutational analysis of role of ADP-ribosylation activity and Gm1-binding activity in the adjuvant properties of theEscherichia coliheat-labile enterotoxin towards intranasally administered keyhole limpet hemocyanin”Eur. J. Immunol. 28:1243-1250 (1998).
Douce et al., “Intranasal Immunogenicity and Adjuvanticity of Site-Directed Mutant Derivatives of Cholera Toxin”Infection and Immunity65(7):2821-2828 (Jul. 1997).
Douce et al., “Mutants ofEscherichia coliheat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants”Proc. Natl. Acad. Sci. USA92:1644-1648 (Feb. 1995).
Elson et al., “Morphologic and Functional Alterations of Mucosal T Cells by Cholera Toxin and its B Subunit”J. Immunol. 154:1032-1040 (1995).
Elson, “Cholera Toxin as a Mucosal Adjuvant”Mucosal Vaccines, Academic Press. San Diego pp. 59-72 (1996).
Hammer et al., “Spontaneous Inflammatory Disease in Transgenic Rats Expressing HLA-B27 and Human β2m: An Animal Model of HLA-B27-Associated Human Disorders”Cell63;1099-1112 (Nov. 30, 1990).
Kühu et al., “Interleukin-10-Deficient Mice Develop Chronic Enterocolitis”Cell75:263-274 (Oct. 22, 1993)3
Lebens et al., “Large-Scale Production ofVibrio choleraeToxin B Subunit for Use in Oral Vaccines”Bio/Technology11:1574-1578 (Dec. 11, 1993).
Lycke, “The Mechanism of cholera toxin adjuvanticity”Res. Immunol. 148:504-520 (Dec. 31, 1997).
McSorley etal., “Selective tolerizatiom of TH1-Like cells after nasal administration of a cholera toxid-LACK conjugate”Eur. J. Immunol. 28:424-432 (1998).
Mekalanos et al., “Cholera toxin genes: nucleotide sequence, deletion analysis and vaccine development”Nature306:551-557 (Dec. 8, 1983).
Mombaerts et al., “Spontaneous Development of Inflammatory Bowel Disease in T Cell Reeptor Mutant Mice”Cell75:275-282 (Oct. 22, 1993).
Neurath et al., “Antibodies to Interleukin 12 Abrogate Established Experimental Colitis On Mice”J. Exp. Med. 182:1281-1290 (Nov. 1995).
Podolsky, “Inflammatory Bowel Disease”New Engl. J. Med. 325:928-937 (Sep. 26, 1991).
Powrie et al., “Inhibition of Th1Responses Prevents Inflammatory Bowel Disease inscidMice reconstituted with CD45RBhiCD4' T Cells”Immunity1:553-562 (Oct. 1994).
Sadlack et al., “Ulcerative Colitis-Like Disease in Mice with a Disrupted Interleukin-2 Gene”Cell75:253-261 (Oct. 22, 1993).
Snider, “The Mucosal Adjuvant Activities of ADP-Ribosylating Bacterial Enterotoxins”Crit Rev. Immunol. 15(3&4) : 317-348
Strober et al., “Reciprocal IFN-γ and TGF-β responses Regulate the occurence of mucosal inflammation”Immunol. Today18(2) : 61-64 (Feb. 1, 1997).
Strober and Ehrhardt, “Chronic Intestinal Inflammation: An Unexpected Outcome on Cytokine or T cell Receptor Mutant Mice”Cell75:203-205 (Oct. 22, 1993).
Strober and Neurath, “Immunological diseases of the gastrointestinal tract”Clinical Immunology-Principles and Practice(R.R. Rich, ed) Mosby, St. Louis, Chapter 94 pp. 1401-1428 (1995).
Sun et al. “Cholera toxin B subunit: An efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance”Proc. Natl. Acad. Sci. USA91:10795-10799 (Nov. 1994).
Van der Heijden and Stok, “Improved procedure for the isolation of functionally active lymphoid cells from the murine intestine”J. Immunol. Meth. 103:161-167 (1987).
Woogen et al., “Inhibition of Murine T Cell Activation by Cholera Toxin B Subunit is not Mediated through the Phosphatidylinositol Second Messenger System”J. Immunol. 150:3274-3283 (Apr. 15, 1993).
Woogen et al., “Inhibition of murine lymphocyte proliferation by the B subunit of cholera toxin”J. Immunol. 139:3764-3770 (Dec. 1, 1987).
Yankelev
Boirivant Monica
Fuss Ivan J.
Kelsall Brian L.
Stober Warren
Needle & Rosenberg P.C.
Portner Ginny Allen
Smith Lynette R. F.
The United States of America as represented by the Department of
LandOfFree
Methods of treating inflammatory bowel disease using cholera... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating inflammatory bowel disease using cholera..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating inflammatory bowel disease using cholera... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3529017